U S Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- U S Pharmaceuticals's estimated annual revenue is currently $2.2M per year.
- U S Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- U S Pharmaceuticals has 11 Employees.
- U S Pharmaceuticals grew their employee count by -27% last year.
U S Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|
U S Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is U S Pharmaceuticals?
U S Pharmaceuticals is presently a distributor of Anti-Rabies vaccines,oncology products,health supplements,human life products and all other pharmaceutical products.We also deal in our own medicine brands. We have been providing best quality products and services in all health related sectors since last 18 years.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$2.2M
Revenue (est)
-27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
U S Pharmaceuticals News
The award, presented in partnership with Mitsubishi Tanabe Pharma America, Inc. (MTPA), will be featured at the upcoming Target ALS Annual...
Covid Helped Drive US Pharmaceuticals Spending Up 12% In 2021. A study shows the cost of covid vaccines and therapies played a part in a large...
Romanelli led Merck's business in China for five years before departing in July 2021 to run the privately held biotech Ji Xing Pharmaceuticals.
Other Companies in Agra
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.6M | 18 | 6% | N/A |
#2 | N/A | 23 | -4% | N/A |
#3 | $3M | 24 | 4% | N/A |
#4 | N/A | 26 | 8% | N/A |
#5 | N/A | 33 | 6% | N/A |